About 4-hydroxybenzoate polyprenyltransferase, mitochondrial
4-hydroxybenzoate polyprenyltransferase, mitochondrial (COQ2) is a protein
from Homo sapiens identified by UniProt accession
Q96H96, 371 residues long.
MolForge cross-references it against 0 known binders and
88 disease associations.
Target properties
| Protein name | 4-hydroxybenzoate polyprenyltransferase, mitochondrial |
| UniProt accession | Q96H96 |
| Gene | COQ2 |
| Organism | Homo sapiens |
| Length | 371 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (88)
Diseases linked to this target (Open Targets).
- coenzyme Q10 deficiency, primary, 1 · score 0.80
- neurodegenerative disease · score 0.53
- multiple system atrophy · score 0.50
- coenzyme Q10 deficiency · score 0.48
- monocyte count · score 0.43
- blood protein measurement · score 0.41
- mitochondrial disease · score 0.37
- genetic disorder · score 0.34
- monocyte percentage of leukocytes · score 0.33
- nephrotic syndrome · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96H96-F1 | alphafold | PREDICTED | 85.30 | — |
Amino-acid sequence (371 residues)
MLGSRAAGFA RGLRAVALAW LPGWRGRSFA LARAAGAPHG GDLQPPACPE PRGRQLSLSA AAVVDSAPRP LQPYLRLMRL DKPIGTWLLY LPCTWSIGLA AEPGCFPDWY MLSLFGTGAI LMRGAGCTIN DMWDQDYDKK VTRTANRPIA AGDISTFQSF VFLGGQLTLA LGVLLCLNYY SIALGAGSLL LVITYPLMKR ISYWPQLALG LTFNWGALLG WSAIKGSCDP SVCLPLYFSG VMWTLIYDTI YAHQDKRDDV LIGLKSTALR FGENTKPWLS GFSVAMLGAL SLVGVNSGQT APYYAALGAV GAHLTHQIYT LDIHRPEDCW NKFISNRTLG LIVFLGIVLG NLWKEKKTDK TKKGIENKIE N
Explore 4-hydroxybenzoate polyprenyltransferase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets